See the DrugPatentWatch profile for stiripentol

Stiripentol is a medication primarily used for the treatment of Dravet syndrome, a rare and severe form of epilepsy that begins in infancy or early childhood [1]. This anticonvulsant is often preferred for seizure control in Dravet syndrome due to its unique mechanism of action. Unlike many other antiepileptic drugs, stiripentol modulates the neurotransmitter release and neuronal excitability, which can help reduce the frequency and severity of seizures associated with Dravet syndrome [1][2].

Stiripentol is typically used in combination with other antiepileptic drugs, such as clobazam, and is often introduced when other treatments have proven ineffective [1][2]. Its use is supported by several clinical trials and studies that have demonstrated its efficacy in reducing seizure frequency and severity in patients with Dravet syndrome [1][2].

In summary, stiripentol is preferred for seizure control in cases of Dravet syndrome, particularly when other treatments have been unsuccessful. Its unique mechanism of action and demonstrated efficacy make it a valuable option for managing this severe form of epilepsy [1][2].

Sources:
[1] DrugPatentWatch.com. (2021). Stiripentol. Retrieved from <https://www.drugpatentwatch.com/drugs/stiripentol>
[2] ClinicalTrials.gov. (2021). Stiripentol for Severe Myoclonic Epilepsy in Infancy. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT00087091>